MCRN-003 / CCTG MYX.1 - A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies

Time: Saturday, December 1, 2018: 6:00 – 8:00 PM
Location: Hall GH (San Diego Convention Centre)
Type: Paper
Session: 653 - Myeloma: Therapy, excluding Transplantation: Poster I
Presenter: Christopher Venner
Abstract: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies (#1984)
Authors: Christopher P. Venner, Richard Leblanc, Irwindeep Sandhu, Darrell J. White, Andrew R Belch, Donna E Reece, Christine I Chen, Sean Dolan, Andrea Kew, Marc Lalancette, Martha L Louzada, Arleigh McCurdy, Gail T. McDonald, Tony Reiman, Laura Rodriguez, Lois E. Shepherd, Engin Gul, Bingshu E. Chen, and Annette E. Hay
Link: https://ash.confex.com/ash/2018/webprogram/Paper117824.html

Alliance A041202 / CCTG CLC.2 – A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ≥ 65 years of age) with Chronic Lymphocytic Leukemia (CLL)

Time: Sunday, December 2, 2018: 2:00 – 4:00 PM
Location: Hall AB (San Diego Convention Center)
Type: Oral
Session: Plenary Scientific Session
Presenter: Frank G. Rucker
Abstract: Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202 (#6)
Link: https://ash.confex.com/ash/2018/webprogram/Paper116653.html
Alliance A10603 / CCTG ALC.2 - A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)

Time: Sunday, December 2, 2018: 5:00 PM  
Location: Seaport Ballroom F (Manchester Grand Hyatt San Diego)  
Type: Oral  
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Minimal Residual Disease and Genetic Characterization  
Hematology Disease Topics & Pathways: AML, Diseases, Adult, Study Population, Clinically relevant, Myeloid Malignancies  
Presenter: Frank G. Rucker  
Abstract: **Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (#435)**  

CCTG LY.10 - A Phase II Study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) in Patients With Either Hodgkin's Disease or Aggressive Histology Non-Hodgkin's Lymphoma Which is Relapsed or Refractory

Time: Sunday, December 2, 2018: 6:00 – 8:00 PM  
Location: Hall GH (San Diego Convention Centre)  
Type: Paper  
Session: 627 - Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster II  
Presenter: Mina Dehghani Mohammadabadi  
Abstract: **Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy - Analysis of Canadian Cancer Trials Group (CCTG) LY.10 Trial (#2980)**  
Authors: Mina Dehghani Mohammadabadi, Annette E. Hay, Lois E. Shepherd, Michael Crump, Bingshu E Chen, and Tara Baetz  